Archives: Agenda

• Imperial Brands role in reducing harm
• Everything starts with the consumer
• Enforceable, proportionate regulation to maximise harm reduction

• Regulation and harm reduction in key markets
• How are key markets responding to illicit products
• How are international policies and regulations affecting US regulations and vice versa
• The Tobacco and Vapes Bill: Implications of the U.K Generation Ban

-Will other nations follow suit?

• Implications of recent US Regulations under the New Administration: Withdrawal of plan to ban menthol cigarettes in the United States

Moderator: Willie McKinney, CEO, McKinney Specialty Labs

Panelists

Tobias Baude, Director of Corporate Affairs for NGP, Imperial Brands

Dr. Jessica Zdinak, Founder & Chief Research Officer, Applied Research and Analysis Company (ARAC)

Sarah Marking, Co-Founder and Chief Strategy Officer, Sanova

Joe Smith, Partner, Thompson Hine

Marina Murphy, Senior Director of Scientific Affairs, Haypp Group

Sponsored by AmeriNic

• Leveraging microfluidics to replace the wick and coil
• Using silicon chip manufacturing techniques to make the quantum chip
• Quantum vape performance relative to market leading vapes

• Implications of recent changes at CTP and how they may shape regulatory priorities
• The outlook on enforcement against illicit e-vapor and nicotine pouch products
• Improving the PMTA process to accelerate authorization of smoke-free products
• Assessing the regulatory impact of recent court rulings on product authorizations

Moderator: Agustin Rodriquez, Partner, Troutman Pepper Locke

Panelists

Lillian Ortega, Owner & Chief Regulatory Strategist, WOW Solutions LLC

And Former Director, Division of Enforcement and Manufacturing (Center for Tobacco Products), FDA

Azim Chowdhury, Partner, Keller and Heckman

Guy Bentley, Director of Consumer Freedom, Reason Foundation

• An introduction covering why DVCR? DVCR’s capabilities, facilities and investment
• Individual risk assessment, clinical work on nicotine exposure, abuse liability and biomarkers
• Performance of candidate products in the real world, risk comprehension, TPPI and actual use studies